Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bevacizumab
  • Fallopian Tube Neoplasms
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Peritoneal Neoplasms

abstract

  • On the basis of the PFS, overall response rate, and tolerability of these two antivascular therapies, further evaluation is warranted for this chemotherapy-free regimen. Fosbretabulin in combination with bevacizumab increases the risk of hypertension.

publication date

  • July 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4962710

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.8153

PubMed ID

  • 27217446

Additional Document Info

start page

  • 2279

end page

  • 86

volume

  • 34

number

  • 19